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INTRODUCTION
Since its introduction in 1974, endoscopic biliary sphincterot-
omy (EST) has been the standard therapy for the removal of 
bile duct stones.1,2 The safety of EST has been well established, 
and its use has become widespread. There have been many re-
ports of bile duct stone recurrence after EST, although the range 
of reported recurrence rates is wide (3% to 24%).3-8 The suggest-
ed causes of recurrent bile duct stones after EST are cholecys-
tolithiasis, mechanical lithotripsy, pneumobilia, a dilated com-
mon bile duct (CBD), periampullary diverticulum, angulation 
of the CBD (≤145°) on endoscopic retrograde cholangiopancre-
atography (ERCP), bile stasis, biliary stricture, and papillary ste-
nosis.6,7,9,10
Cholecystectomy in patients with an intact gallbladder (GB) 
after endoscopic removal of stones from the CBD remains a 
matter of debate.11 Several prospective randomized trials have 
shown that cholecystectomy after endoscopic treatment of 
bile duct stones reduces recurrent biliary events and is recom-
mended.12,13 Several previous trials recommended elective cho-
lecystectomy after EST in cases of GB calculi, preexisting chol-
angitis, acute biliary pancreatitis, complete opacification of the 
GB during ERCP, and non-visualization of the GB after EST;14,15 
however, other studies have shown that elective cholecystecto-
my after EST does not reduce the incidence of recurrent biliary 
complications.16-20 Although cholecystectomy after endoscopic 
removal of CBD stones reduced recurrent CBD stones in some 
Cholecystectomy for Prevention of Recurrence after 
Endoscopic Clearance of Bile Duct Stones in Korea
Myung Eun Song, Moon Jae Chung, Dong-Jun Lee, Tak Geun Oh, Jeong Youp Park, Seungmin Bang,  
Seung Woo Park, Si Young Song, and Jae Bock Chung
Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Purpose: Cholecystectomy in patients with an intact gallbladder after endoscopic removal of stones from the common bile duct 
(CBD) remains controversial. We conducted a case-control study to determine the risk of recurrent CBD stones and the benefit of 
cholecystectomy for prevention of recurrence after endoscopic removal of stones from the CBD in Korean patients. 
Materials and Methods: A total of 317 patients who underwent endoscopic CBD stone extraction between 2006 and 2012 were 
included. Possible risk factors for the recurrence of CBD stones including previous cholecystectomy history, bile duct diameter, 
stone size, number of stones, stone composition, and the presence of a periampullary diverticulum were analyzed.
Results: The mean duration of follow-up after CBD stone extraction was 25.4±22.0 months. A CBD diameter of 15 mm or larger 
[odds ratio (OR), 1.930; 95% confidence interval (CI), 1.098 to 3.391; p=0.022] and the presence of a periampullary diverticulum 
(OR, 1.859; 95% CI, 1.014 to 3.408; p=0.045) were independent predictive factors for CBD stone recurrence. Seventeen patients 
(26.6%) in the recurrence group underwent elective cholecystectomy soon after endoscopic extraction of CBD stones, compared 
to 88 (34.8%) in the non-recurrence group; the difference was not statistically significant (p=0.212).
Conclusion: A CBD diameter of 15 mm or larger and the presence of a periampullary diverticulum were found to be potential 
predictive factors for recurrence after endoscopic extraction of CBD stones. Elective cholecystectomy after clearance of CBD 
stones did not reduce the incidence of recurrent CBD stones in Korean patients.
Key Words:  Cholecystectomy, gallstones, common bile duct, recurrence
Yonsei Med J 2016 Jan;57(1):132-137
http://dx.doi.org/10.3349/ymj.2016.57.1.132
Original Article 
pISSN: 0513-5796 · eISSN: 1976-2437
Received: July 25, 2014   Revised: January 22, 2015
Accepted: February 12, 2015
Corresponding author: Dr. Moon Jae Chung, Division of Gastroenterology, De-
partment of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-
ro, Seodaemun-gu, Seoul 03722, Korea.
Tel: 82-2-2228-1981, Fax: 82-2-393-6884, E-mail: mjchung@yuhs.ac
•The authors have no financial conflicts of interest.
© Copyright: Yonsei University College of Medicine 2016
This is an Open Access article distributed under the terms of the Creative Com-
mons Attribution Non-Commercial License (http://creativecommons.org/ licenses/
by-nc/3.0) which permits unrestricted non-commercial use, distribution, and repro-
duction in any medium, provided the original work is properly cited.
133http://dx.doi.org/10.3349/ymj.2016.57.1.132
Myung Eun Song, et al.
studies of Caucasian patients, the data was inconclusive in 
Asians due to differences in stone composition. We conducted 
a case-control study to determine the risk of recurrent CBD 
stones and to evaluate the need for subsequent cholecystecto-
my in order to prevent recurrence after endoscopic removal of 
stones from the CBD in Korean patients. 
MATERIALS AND METHODS
Patients
Patients enrolled in this study met the following criteria: 1) 
ERCP with EST performed between January 2006 and January 
2012 at Severance Hospital, 2) the presence of CBD stones and 
their complete clearance documented by cholangiography, 3) 
GB in situ documented by abdominal ultrasonography or ab-
dominal computed tomography at the time of initial ERCP, 4) 
no evidence of underlying advanced malignancy, 5) no evi-
dence of intrahepatic duct stones or bile duct stricture, and 6) 
follow-up longer than 3 months after ERCP.
Sixty-four patients with recurrent bile duct stones after CBD 
stone extraction by ERCP (recurrence group) between 2006 
and 2012 were included in this study. For each patient of this 
recurrence group, four propensity-score age- and sex-matched 
control patients (non-recurrence group) were enrolled. A total 
of 317 patients who underwent endoscopic CBD stone extrac-
tion were studied.
Definitions and main outcome measures
Patient clinical data were obtained prospectively from a pa-
tient database. Possible risk factors for the recurrence of CBD 
stones including history of cholecystectomy, previous Bill-
roth-II operation, bile duct diameter, stone size, number of 
stones, stone composition, periampullary diverticulum, me-
chanical lithotripsy, multiple ERCP sessions, and use of urso-
deoxycholic acid (UDCA) and/or Rowachol® (Rowa Pharma-
ceuticals Ltd., Newtown, Bantry, Co. Cork, Ireland) medication 
were analyzed. The entry date was the time of complete endo-
scopic removal of CBD stones. The follow-up durations were 
determined from the entry date to the last visit date. The recur-
rence-free duration was determined from the entry date to the 
occurrence of a recurrent bile duct stone or the last visit date. 
The following data were noted before EST: gender, age, body 
mass index (BMI), total bilirubin level, jaundice, the presence 
or absence of a periampullary diverticulum, bile duct diame-
ter, and the number and sizes of stones. A periampullary diver-
ticulum was defined as the presence of a diverticulum within a 
radius of 2–3 cm from the ampulla of vater and was divided 
into the following three types according to the position be-
tween the major papilla and diverticulum: type 1, papilla lo-
cated deep within the diverticulum (intra-diverticular papil-
la); type 2, papilla located on the inner rim of the diverticulum 
(juxta-papillary diverticulum) in such a way that the papillary 
orifice was not visible endoscopically; and type 3, papilla lo-
cated outside the diverticulum (extra-diverticular papilla) in 
such a way that the papillary orifice was easily detectable.7,21,22 
The recurrence of bile duct stones was defined as develop-
ment of stones not earlier than 3 months after the complete 
removal of previous bile duct stones. The diagnosis of recur-
rent choledocholithiasis was made based on clinical symp-







Age (mean±SD, yrs) 65.6±12.1 63.0±12.0 66.9±11.9 0.006
Gender (male/female) 144/173 (45.4/54.6) 51/54 (48.6/51.4) 93/119 (43.9/56.1) 0.429
BMI (mean±SD, kg/m2) 23.3±3.1 23.8±3.0 23.0±3.1 0.038
Total bilirubin (mean±SD, mg/dL) 1.8±2.5 1.8±2.0 1.8±2.7 0.955
Jaundice (yes/no) 60/257 (18.9/81.1) 21/84 (20/80) 39/173 (18.4/81.6) 0.732
UDCA and/or Rowachol® medication (yes/no) 287/30 (90.5/9.5) 103/2 (98.1/1.9) 184/28 (86.8/13.2) 0.001
Cholelithiasis (yes/no) 187/130 (59/41) 104/1 (99/1) 83/129 (39.2/60.8) <0.001
CBD diameter (mean±SD, mm) 15.3±4.9 14.5±4.0 15.6±5.2 0.128
Bile duct stone diameter ≥15 mm (yes/no) 77/240 (24.3/75.7) 22/83 (21/79) 55/157 (25.9/74.1) 0.329
Bile duct stone number ≥5 (yes/no) 113/204 (35.6/64.4) 41/64 (39/61) 72/140 (34/66) 0.374
Stone composition (brown pigment/cholesterol) 159/158 (50.2/49.8) 55/50 (52.4/47.6) 104/108 (49.1/50.9) 0.577
Previous Billroth-II operation (yes/no) 17/300 (5.4/94.6) 4/101 (3.8/96.2) 13/199 (6.1/93.9) 0.388
Periampullary diverticulum (yes/no) 81/236 (25.6/74.4) 33/72 (31.4/68.6) 48/164 (22.6/77.4) 0.091
Mechanical lithotripsy (yes/no) 19/298 (6/94) 3/102 (2.9/97.1) 16/196 (7.5/92.5) 0.098
Multiple sessions of ERCP (≥2, yes/no) 60/257 (18.9/81.1) 15/90 (14.3/85.7) 45/167 (21.2/78.8) 0.138
Recurrence-free duration (mean±SD, months) 24.4±21.5 27.9±24.4 22.6±19.8 0.223
Follow-up duration (mean±SD, months) 25.4±22.0 28.2±24.3 24.0±20.6 0.365
ERCP, endoscopic retrograde cholangiopancreatography; SD, standard deviation; BMI, body mass index; UDCA, ursodeoxycholic acid; CBD, common bile duct.
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toms, the laboratory alteration, and the radiological visualiza-
tion of bile duct stones. All recurrent CBD stones were confi-
rmed by ERCP.
ERCP procedures
All ERCP procedures were performed using side-viewing en-
doscopes (TJF-260V or TJF-240; Olympus Optical Co., Tokyo, 
Japan). These ERCPs were carried out by experienced endos-
copists (J.B.C., S.Y.S., S.W.P., S.M.B., J.Y.P., and M.J.C.). A pull-
type sphincterotome (Clever-cut; Olympus, Athens, Greece) or 
needle knife (MicroKnifeTM XL, Boston Scientific, Marlbor-
ough, MA, USA) with or without a guide wire (Jagwire, Micro-
vasive, Boston Scientific, Marlborough, MA, USA) was applied 
in cases of difficult CBD cannulation. For stones that were too 
large for removal in one session, an endoscopic mechanical 
lithotripsy was attempted in order to fragment the stones. 
When incomplete stone removal was suspected at the end of 
the procedure, an endoscopic nasobiliary drainage or plastic 
stent was inserted in order to prevent cholangitis.
Statistical analysis
Categorical variables were analyzed with chi-squared tests, 
while continuous variables (expressed as means with stan-
dard deviations) were analyzed using Student’s t-test. We con-
ducted the Mann-Whitney U test for nonparametric statistical 
analyses to identify statistical differences in recurrence risk 
factors. Potential risk factors were assessed by a multivariate 
logistic regression model. Cumulative recurrence rates of bile 
duct stones during the follow-up intervals were compared us-
ing the Kaplan-Meier method, and the statistical significance 
of the difference between them was examined by the log-rank 
test. A p-value of less than 0.05 was considered statistically 
significant. All statistical analyses were performed using SPSS 
version 20.0 (IBM SPSS, New York, USA).
RESULTS
Patient characteristics
Characteristics of the 317 patients are shown in Table 1. The 
mean age was 65.6±12.1 years; there were 173 women (54.6%) 
and 144 men (45.4%). Mean BMI was 23.3±3.1 kg/m2. Most of 
the patients (90.5%) had taken the UDCA and/or Rowachol® 
after endoscopic removal of bile duct stones. Patients were fol-
lowed-up for a mean period of 25.4±22.0 months. The incid-
ence of cholelithiasis was higher in the cholecystectomy group 
before cholecystectomy than in the non-cholecystectomy 
group (99.0% vs. 39.2%; p<0.001).
Risk factors for recurrence of CBD stones
Possible risk factors associated with recurrence of bile duct 
stones, including age, gender, BMI, total bilirubin level, jaun-
dice, use of UDCA and/or Rowachol® medication after endo-
scopic removal of bile duct stones, cholelithiasis, the size of the 
Table 2. Univariate Analysis of Risk Factors for Recurrent Bile Duct Stones in Terms of Patient Clinical Characteristics and ERCP Findings between the 
Recurrence Group and the Non-Recurrence Group at Initial ERCP
Risk factor
Patients with recurrent stone,
n=64 (20.2%)
Patients without recurrent stone,
n=253 (79.8%)
p value
Age (mean±SD, yrs) 67.8±12.2 65.1±12.0 0.134
Gender (male/female) 26/38 (40.6/59.4) 118/135 (46.6/53.4) 0.388
BMI (mean±SD, kg/m2) 23.2±3.0 23.3±3.1 0.805
Total bilirubin (mean±SD, mg/dL) 1.4±1.4 1.9±2.7 0.227
Jaundice (yes/no) 9/55 (14.1/85.9) 51/202 (20.2/79.8) 0.266
UDCA and/or Rowachol® medication (yes/no) 59/5 (92.2/7.8) 228/25 (90.1/9.9) 0.613
Cholelithiasis (yes/no) 34/30 (53.1/46.9) 153/100 (60.5/39.5) 0.286
CBD diameter (mean±SD, mm) 16.1±4.1 15.0±5.1 0.046
CBD diameter ≥15 mm (yes/no) 38/26 (59.4/40.6) 109/144 (43.1/56.9) 0.020
Bile duct stone diameter ≥15 mm (yes/no) 18/46 (28.1/71.9) 59/194 (23.3/76.7) 0.423
Bile duct stone number ≥5 (yes/no) 20/44 (31.2/68.8) 93/160 (36.8/63.2) 0.411
Stone composition (brown pigment/cholesterol) 36/28 (56.2/43.8) 123/130 (48.6/51.4) 0.275
Cholecystectomy (yes/no) 17/47 (26.6/73.4) 88/165 (34.8/65.2) 0.212
Previous Billroth-II operation (yes/no) 2/62 (3.1/96.9) 15/238 (5.9/94.1) 0.540
Periampullary diverticulum (yes/no) 22/42 (34.4/65.6) 59/194 (23.3/76.7) 0.070
Mechanical lithotripsy (yes/no) 4/60 (6.2/93.8) 15/238 (5.9/94.1) 0.999
Multiple sessions of ERCP (≥2, yes/no) 16/48 (25/75) 44/209 (17.4/82.6) 0.165
Recurrence-free duration (mean±SD, months) 21.2±14.6 25.2±22.9 0.844
Follow-up duration (mean±SD, months) 26.4±17.8 25.2±22.9 0.088
ERCP, endoscopic retrograde cholangiopancreatography; SD, standard deviation; BMI, body mass index; UDCA, ursodeoxycholic acid; CBD, common bile duct.
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CBD, the number, sizes, and types of stones, cholecystectomy, 
Billroth II gastrectomy, periampullary diverticulum, mechani-
cal lithotripsy, and multiple ERCP sessions are listed in Table 
2. The mean duration of follow-up after CBD stone extraction 
was 26.4±17.8 months in the recurrence group and 25.2±22.9 
months in the non-recurrence group (p=0.088). Of the 64 pa-
tients in the recurrence group, 17 (26.6%) underwent elective 
cholecystectomy soon after endoscopic extraction of CBD 
stones compared to 88 (34.8%) of the 253 patients in the non-
recurrence group, a difference which was not statistically sig-
nificant (p=0.212). There was no significant difference be-
tween the recurrence group and the non-recurrence group in 
terms of the presence of gallstones (p=0.286).
On univariate analysis, the diameter of the CBD was a sig-
nificant contributor to the recurrence of CBD stones. The mean 
diameter of the CBD in the recurrence group was 16.1±4.1 mm, 
whereas that in the non-recurrence group was 15.0±5.1 mm 
(p=0.046). A CBD diameter of 15 mm or larger was identified 
as a predictive factor for the recurrence of CBD stones (p= 
0.020). Of the 317 patients, 159 (50.2%) had brown pigment 
stones at initial ERCP. Such brown pigment stones (39 cases, 
60.9%) were more common in cases of recurrence than choles-
terol stones (25 cases, 39.1%).
Multivariate analysis determined that a CBD diameter of 15 
mm or larger [odds ratio (OR), 1.930; 95% confidence interval 
(CI), 1.098 to 3.391; p=0.022] and the presence of a periampul-
lary diverticulum (OR, 1.859; 95% CI, 1.014 to 3.408; p=0.045) 
were independent predictive factors for CBD stone recurrence 
(Table 3). Elective cholecystectomy was not a risk factor for re-
currence (p=0.198).
Comparison of the cholecystectomy and 
non-cholecystectomy groups
During the follow-up period, 105 (33.1%) of 317 patients with GB 
in situ underwent cholecystectomy after ERCP with EST (cho-
lecystectomy group), and the remaining 212 patients (66.9%) 
did not undergo cholecystectomy (non-cholecystectomy gro-
up). There were no significant differences between the two 
groups in terms of gender distribution, total bilirubin level, ja-
undice, CBD size, or the number, sizes, and types of stones at 
initial ERCP. The patients in the cholecystectomy group (mean, 
63.0±12.0 years) were younger than those in the non-chole-
cystectomy group (mean, 66.9±11.9 years; p=0.006). 
Kaplan-Meier analysis revealed that the cumulative recur-
rence rate of CBD stones between the cholecystectomy group 
and the non-cholecystectomy group was not significantly dif-
ferent (p=0.278) (Table 4, Fig. 1). At 5 years, the cumulative 
probabilities of CBD stone recurrence in the cholecystectomy 
and the non-cholecystectomy groups were 44.3% and 40.6%, 
respectively. In patients with cholelithiasis, there was no dif-
ference in the cumulative recurrence rate of CBD stones be-
tween the cholecystectomy group and the non-cholecystecto-
my group (p=0.279) (Table 4).
Table 3. Multivariate Analysis of Predictive Factors for the Recurrence 
of CBD Stones Identified Using a Logistic Regression Model
Variables p value OR (95% CI)
CBD diameter ≥15 mm  0.022 1.930 (1.098–3.391)
Cholecystectomy 0.198 0.663 (0.354–1.240)
Periampullary diverticulum 0.045 1.859 (1.014–3.408)
OR, odds ratio; CI, confidence interval; CBD, common bile duct.
Table 4. Cumulative Recurrence Rates of Common Bile Duct Stones in Patients Who Underwent Cholecystectomy and Those Who Did Not
No. of patients (%)
Cumulative recurrence rate
p value
1 yr 2 yrs 3 yrs 5 yrs
Total 0.278
Cholecystectomy 105 (33.1) 0.069 0.105 0.245 0.443
Non-cholecystectomy 212 (66.9) 0.121 0.232 0.327 0.406
Cholelithiasis (+) 0.279
Cholecystectomy 104 (55.6) 0.069 0.105 0.245 0.443
Non-cholecystectomy 83 (44.4) 0.147 0.234 0.340 0.379
Fig. 1. Probability of remaining free of common bile duct stone recur-
rence after endoscopic common bile duct stone extraction in patients 
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DISCUSSION
Previous studies reported risk factors for the recurrence of bile 
duct stones in post-EST patients.6,7,9,10 Significant risk factors 
were an intact GB with cholecystolithiasis, mechanical litho-
tripsy, pneumobilia, dilated CBD, periampullary diverticu-
lum, angulation of the CBD (≤145°) on ERCP, bile stasis, bili-
ary stricture, and papillary stenosis. In the present study, 
significant risk factors were bile duct diameter and the pres-
ence of a periampullary diverticulum. The diameter of the bile 
duct is already known to be an important predictor for bile duct 
stone recurrence. Some authors have identified a bile duct di-
ameter ≥15 mm as a risk factor for recurrent stones.8,23 The di-
ameter of the dilated bile duct does not decrease after removal 
of the stone, as the elasticity of the duct wall is lost due to chr-
onic inflammation and fibrosis. A dilated bile duct may result 
in bile stasis and bacterial infection, which are potential risk 
factors for recurrent stones.23,24 In addition, periampullary di-
verticula compress the distal CBD anatomically, leading to 
bile stasis and bacterial infection of the bile duct via the orifice 
of the sphincter of Oddi.21 Bile stasis associated with a type 1 
or 2 diverticulum could be caused by either mechanical fac-
tors or the presence of coexisting motility disorders involving 
the sphincter of Oddi.7,25 In addition, large stones often re-
quire mechanical lithotripsy. Mechanical lithotripsy is likely 
to increase the risk of recurrence, as even a few missed small 
stone fragments may act as nidi for stone reaggregation.8 How-
ever, in the present study, large stones and mechanical litho-
tripsy were not significant risk factors for recurrence. 
CBD stones are classified as primary and secondary stones 
based on etiology and pathogenesis. A primary stone in the 
CBD indicates that it was formed within the bile duct, whereas 
the term secondary indicates a stone that has migrated from 
the original site where it was formed. Primary bile duct stones 
can form in the bile duct several years after cholecystectomy, 
and most are brown pigment stones (calcium bilirubinate sto-
nes). On the contrary, secondary bile duct stones usually form 
in the GB and consist predominately of cholesterol.25 In recent 
studies, prophylactic cholecystectomy did not reduce the for-
mation of recurrent CBD stones or additional recurrent chol-
angitis after CBD stone removal by EST in Korean patients, in 
whom brown pigment stones are more common.19,20 Similar-
ly, in the present study, cholecystectomy was not associated 
with a reduction in the recurrence rate of bile duct stones. The 
cumulative recurrence rate of CBD stones between the chole-
cystectomy group and the non-cholecystectomy group was not 
significantly different. This finding can be explained by the 
fact that bile duct stone recurrence occurred more frequently 
due to brown pigment stones than due to cholesterol stones in 
this study. Brown pigment stones more commonly form in the 
bile duct, rather than migrate from the GB; thus, cholecystec-
tomy would not affect the risk of bile duct stone recurrence in 
this setting.
In a recent study, patients with a calculous GB had a signifi-
cantly higher rate of recurrent biliary complication than the 
acalculous GB group or the cholecystectomy group.26 In anoth-
er study, the recurrence rates of CBD stones were not signifi-
cantly different between the patients with and without gall-
stones within the GB in situ group.19 In the present study, there 
was no association of the relationship between gallstones and 
recurrent CBD stones in patients with choledocholithiasis af-
ter endoscopic treatment. This can indicates that the majority 
of CBD stones are likely secondary stones that migrated from 
the GB in Western patients, whereas primary stones are likely 
to be formed within the bile duct in Korean patients.
UDCA is currently used in the medical treatment of gall-
stones, particularly in patients with mild symptoms (i.e., with-
out pancreatitis, cholecystitis, or cholangitis) and a small 
stone size (<10 mm), as well as those with cholesterol stones 
and a normally functioning GB. Rowachol® is an essential oil 
preparation that increases biliary lipid secretion; used alone, 
it has only weak litholytic properties, although it might have 
advantages when combined with UDCA.27 Gallstone compo-
sition among Asians is known to be different from that of Cau-
casians. Calcium bilirubinate stones are not rare in Koreans, 
and such stones show radiolucency on abdominal X-ray im-
agery. The complete dissolution rate of radiolucent GB stones 
by UDCA is reported to be lower in Asians, despite the efficacy 
of dissolutive agents such as UDCA and Rowachol® in the set-
ting of cholesterol stones, which account for most bile duct 
stones in Caucasians.28 In the present study, use of UDCA 
and/or Rowachol® medication did not significantly reduce 
the recurrence of bile duct stones. Given the fact that pigment 
stones are the most common type of bile duct stone in Korea, 
this discrepancy could be due to geographic and ethnic differ-
ences in CBD stone composition. 
In conclusion, a CBD diameter of 15 mm or larger and the 
presence of a periampullary diverticulum were significant pre-
dictive factors for recurrence after endoscopic extraction of 
CBD stones. For patients with risk factors for bile duct stone 
recurrence, periodic surveillance may be recommended. In 
addition, prophylactic cholecystectomy after clearance of CBD 
stones does not appear to reduce the incidence of recurrent 
CBD stones in Korean patients, in whom pigment stones are 
more common. Further prospective studies are needed to in-
vestigate long-term outcomes in these patients.
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